مواقع التدريسيينجامعة الكوفة
DUNYA HABEEB SHNAIN AL-ARDAWEE
Assistant Professor

DUNYA HABEEB SHNAIN AL-ARDAWEE

0Publications
0Lectures
0News

About

I graduated from the College of Pharmacy, University of Kufa, in the academic year 2014–2015, ranking first in my class and first nationwide in Iraq. Subsequently, I was appointed as a faculty member at the College of Pharmacy, University of Kufa, in recognition of my academic excellence.
Later, I was accepted into the Iraqi Board in Clinical Pharmacy at Medical City, Baghdad, where I completed a four-year program.
I graduated on December 13, 2022, ranked first in my cohort

Publications

4
2025

Impact of Cisplatin on the Incidence of Nephrotoxicity in Patients at the National Oncology Teaching Hospital in Al-Najaf Province, Iraq

AuthorsDunya Habeeb Shnain, Aseel Hadi Abdulameer
JournalSurgery, Gastroenterology and Oncology
Date2025-05-02
Abstract

Background: nephrotoxicity is one of the significant complications of cisplatin. Aim of study: to evaluate the impact of cisplatin on nephrotoxicity in patients at the National Oncology Teaching Hospital in Al-Najaf Province. Patients and methods: An observational, cohort study was conducted by 40 patients at the National Hospital for Oncology and Hematology in Al-Najaf Al-Ashraf, Iraq. Results: The study shows significant differences in urea and creatinine levels before and after cisplatin treatment with p-values of 0.381, 0.036, respectively. Cisplatin treatment significantly increased urea and creatinine levels in both genders, with females experiencing a more pronounced decrease after four months than men. Conclusion: Our findings indicate a high incidence of nephrotoxicity in Cisplatin patients, with males at greater risk than females. This is influenced by Urea and Creatinine levels before, 2 months after, and 4 months after Cisplatin treatment. Keywords: cisplatin, nephrotoxicity, serum creatinine level, BUN levels

2025

Evaluating the Current Practice in The Preventing of Venous Thromboembolism in Hospitalised Patients with Cancer in Najaf Province, Iraq

AuthorsDunya Habeeb Shnain, Ibtehal Mohammed Khudhair, Karam Khudhair Abbas, Rawaa Shareef, Sara Omar Ahmed
JournalEurasian Journal of Oncology
Date2025-05-30
Abstract

Introduction. Cancer is linked to a hypercoagulable state, resulting in a four-fold increase in the risk of thrombosis, along with an elevated risk of bleeding. Patients with cancer who receive chemotherapy, thromboembolism is considered the second leading cause of mortality. Malignancy is linked to a higher risk for both thromboembolic and hemorrhagic problems. Purpose. To assess the present practice in the prevention of venous thromboembolism in hospitalized cancer patients. Materials and methods. A cross-sectional study, it involved 70 patients and was conducted at the National Teaching Hospital for Oncology in Najaf Governorate, and the monitoring was conducted during the period from September 15 to February 15 and this study revealed that the type of anticoagulant that administered for hospitalize patient with cancer is enoxaparin according to Padua score. Results. The study included 70 participants, predominantly aged 57–70 years (48.6%), with a greater number of females (57.1%) than males (42.9%). Most participants had a weight exceeding 70 kg (67.1%). Conclusion. The study reveals that Enoxaparin is the preferred anticoagulant for hospitalized cancer patients, as it is effective and prevents bleeding, making it the preferred treatment due to the risk of thrombosis. Keywords: cancer, venous thromboembolism, chemotherapy, anticoagulant

2025

Evaluating the current practice in the preventing of nausea and vomiting in hospitalized patients with cancer in Najaf province

AuthorsDunya Habeeb Shnain, Ahmed Emad Mohammed, Rawaa H. Shareef
JournalKufa Journal of Pharmaceutical Sciences
Date2025-03-30
Abstract

Cancer is a group of diseases that cause by genetic or epigenetic alterations in the somatic cells and characterized by uncontrolled cellular growth which may be spread to other organ. Chemotherapy, surgery and radiotherapy that use in treatment of cancer are known risk factors for Nausea and vomiting and higher incidence in patient received chemotherapy and evidence indicates that the absolute danger depends on emetogenicity of chemotherapy, so highly emetogenic drugs have higher incidence for nausea and vomiting .Many types of antiemetic agents with different mechanisms of action have been developed for chemotherapy induce nausea and vomiting. The most commonly used antiemetic agents are 5-HT3 antagonists, corticosteroids, and NK1 receptor antagonists and the aim of this study to evaluate the current practice in the preventing of nausea and vomiting in hospitalized patients with cancer and this study is a cross-sectional study, it involved 100 patients and conducted at National Teaching Hospital for Oncology in Najaf province. The monitoring was conducted during the period from September 15 to November 15 and this study included 100 participants, including male gender (45%) and female gender (55%) with variation in age 24-34y ) % 5 ( ) % ,35-45y (12%), 46-56y (38%), 57-67y(37%) ,68-80y (8%),The duration of antiemetic for 2days (8%) and for 3days 92 ( nausea ,vomiting and diarrhea ) , % and many causes of admission such as for receive chemotherapy (26%), 14 ( . Keywords: Cancer, Chemotherapy, Nausea and vomiting, Antiemetics

2024

Frequency of dyspnea related to intake of ticagrelor or clopidogrel in patients with chronic coronary syndrome undergoing coronary intervention

AuthorsDunya Habeeb Shnain, Ghassan Mohammed Mahmood, Sara Omar Ahmed
JournalCardiovascular therapy and prevention
Date2024-04-29
Abstract

In patients with chronic coronary syndrome, ticagrelor decreases car diovascular events more efficiently than clopidogrel. In several studies investigating novel P2Y12 inhibitors dyspnea has been detected. A rise of adenosine blood levels is supposed to be one of cases of dyspnea induced by ticagrelor. Dyspnea is a prevalent and complex symptom. It is associated with deterioration of the quality of life and hospital readmission. Aim. To determine the frequency of dyspnea related with ticagrelor or clopidogrel intake in patients with stable coronary artery disease undergoing coronary intervention. Also, to determine which patients could continue ticagrelor intake and which patients couldn’t, and show the causes of ticagrelor discontinuation. Material and methods. Between October 2023 and January 2024, an observational prospective comparative case-control study was conducted at Baghdad Heart Center in Baghdad Teaching Hospital in Medical City. In this study, individuals with stable coronary artery disease who just had therapeutic catheterization and dual antiplatelet therapy were included. The patients from group 1 received aspirin and ticagrelor, while those from group 2 received aspirin and clopidogrel. Results. A total of 120 patients were included. With the ticagrelor intake, the severity of dyspnea was classified as mild 64.2% (77 [120]) and moderate 19.1% (23 [120]). About 16.7% (20 [120]) had no dyspnea at all. The difference between patients who continued ticagrelor intake (16%) and those who stopped using it (84%) was significant. With clopidogrel intake no dyspnea was recorded. Conclusions. According to our findings, the risk or occurrence of dys pnea is only evident in patients who received ticagrelor. When com pared to irreversible P2Y12 inhibitors like clopidogrel, the reversible P2Y12 antagonist ticagrelor has a higher incidence of dyspnea in increasing order. Keywords: dyspnea, ticagrelor, clopidogrel, chronic coronary syn drome, coronary intervention.

Lectures

5

News & Announcements

4
News 2025-11-06

from research to reality : translating science into clinical pharmacy

The Clinical Pharmacy Department held a scientific seminar on "Mechanisms for Translating Scientific Knowledge into Effective Clinical Pharmacy Practice." This seminar aimed to highlight the importance of translating scientific research findings into practical applications that contribute to improving the quality of pharmaceutical care and patient outcomes. The seminar addressed mechanisms for applying research evidence in clinical practice and the role of the clinical pharmacist in analyzing studies and utilizing them in evidence-based treatment decisions.

News 2025-11-04

Awareness campaign about early detection of breast cancer

The Clinical Pharmacy Department organized an awareness campaign to mark Breast Cancer Awareness Month, as designated by the World Health Organization. Pharmacy students participated in the campaign, distributing posters highlighting its primary goal and decorating the college's display wall in pink, symbolizing the importance of prevention over cure.

News 2025-11-04

Student scientific activity to raise awareness about diabetes

A group of faculty members from our college, in collaboration with the Student Activities Unit, organized a scientific student activity to raise awareness about diabetes (symptoms, diagnosis, and treatment methods) with a group of fifth-year students.

News 2025-11-04

FDA approves ruxolitinib for vitiligo: a breakthrough in the field of dermatology

A group of faculty members from the College of Pharmacy held a course on vitiligo, the medications used to treat this disease, and the role of ruxolitinib.

View details